As LAG3 gains increasing clinical validation and TIGIT combinations continue to be explored across oncology programs, the need for preclinical tools that reflect the combinatorial nature of checkpoint biology has grown. The PD-L1 × TIGIT × LAG3 trispecific enables investigators to study T-cell exhaustion, immune suppression, and combinatorial checkpoint blockade within a single in vivo system, reducing the variability and experimental complexity associated with multi-agent study designs.

"Checkpoint biology is inherently combinatorial, and researchers increasingly need tools that reflect that complexity," said Kaitlyn Bushey, Director of Development and Strategic Alliances at Bio X Cell. "This trispecific format brings PD-L1, TIGIT, and LAG3 together within a single in vivo system, expanding the experimental approaches available for studying checkpoint interactions."

The antibody was recombinantly engineered with a murine IgG2a constant region for compatibility in standard mouse models and manufactured to Bio X Cell's in vivo-ready quality standards, including ultra-pure, carrier-free formulations and low endotoxin levels designed to minimize reagent-driven variability and support reproducible in vivo studies.

The launch marks the latest example of Bio X Cell’s approach to defining in vivo-ready antibody standards as research demands evolve. By expanding beyond traditional monoclonal antibodies into advanced recombinant formats and custom engineering capabilities, Bio X Cell is helping researchers investigate increasingly complex biological questions across modern preclinical workflows.

Together, these catalog and custom capabilities provide a unified path from early mechanistic discovery through advanced multispecific development, helping research teams maintain continuity in quality, production, and experimental design across the preclinical workflow.

For information on Bio X Cell’s multispecific antibody portfolio and custom engineering capabilities, visit https://bioxcell.com/multispecific-antibodies.

About Bio X Cell
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Introduces First Commercially Available Anti-Mouse Trispecific Antibody for Preclinical Research appeared first on BioXcell.

Summary:

The organoid field continues to expand, as researchers increasingly utilize these 3D cultures for basic research, biomarker discovery, drug development, personalized medicine, and more. As organoid cultures find their way into more laboratories, scientists endeavor to improve upon existing models and solve organoid challenges.

In this webinar, Celeste Nelson and Oscar Abilez will highlight some ways in which researchers are updating organoid models to better recapitulate in vivo conditions and address organoid challenges.

Topics to be covered:

• How to overcome tissue structure heterogeneity in organoid generation
• How the unique mechanisms used by mammals, birds, and reptiles to build lung epithelium inspire strategies for building organoids
• How micropatterned human pluripotent stem cell-derived gastruloids enable in vitro modeling of early-stage cardiac and hepatic vascularization

Speakers:

Celeste Nelson, PhD
Wilke Family Professor in Bioengineering
Professor of Chemical & Biological Engineering and Molecular Biology
Princeton University

Oscar Abilez, MD, PhD
Senior Scientist
Pediatric Cardiac Surgery
Stanford University

Browse Our Webinar Library

The post Developing Solutions for Organoid Challenges appeared first on BioXcell.

Founded in 2011 and headquartered in Chengdu, Sichuan, Chengdu East Creative Technology Co., Ltd. is a leading comprehensive life science enterprise dedicated to providing integrated services across advanced laboratory instruments, equipment, reagents, and consumables. Over more than a decade of continuous growth, Chengdu East Creative Technology Co., Ltd. has expanded its business scope to support a wide range of fields, including biology, medicine, chemical sciences, environmental protection, agriculture, forestry, disease control, and quality and commodity inspection. Its product portfolio spans nearly all disciplines within the life sciences and medical research. 

As a professional biotechnology organization composed of doctors and researchers trained in life science and medical disciplines, Chengdu East Creative Technology Co., Ltd. operates with a strong focus on scientific rigor and customer trust. Guided by its core business philosophy of “Quality First, Integrity‑Based,” the company carefully curates its product offerings and emphasizes efficient, reliable delivery to help research institutions and industry partners advance scientific discovery and industrial development. 

Through this partnership, Bio X Cell expands local access to its portfolio of functional, in vivo‑ready antibodies across China’s rapidly advancing translational and biomedical research landscape. Chengdu East Creative Technology Co., Ltd. will provide direct, regional access to Bio X Cell’s full antibody portfolio, featuring ultrapure, low‑endotoxin formulations specifically designed for sensitive in vivo studies and validated across advanced in vitro applications, including organoid, organ‑on‑chip, and 3D spheroid model systems. 

“Our priority is ensuring researchers have dependable access to antibodies that deliver consistent, reproducible performance in complex biological systems,” said Christopher Conway, CEO of Bio X Cell. “Chengdu East Creative Technology Co., Ltd.’s technical expertise, broad life science reach, and commitment to quality and integrity make them a strong partner for supporting researchers across this region.” 

As the authorized distributor of Bio X Cell products and services for Chengdu and the Sichuan region, Chengdu East Creative Technology Co., Ltd. will manage product ordering, logistics coordination, and local technical support to ensure researchers receive authentic Bio X Cell reagents backed by full manufacturer quality assurances. 

Chengdu East Creative Technology Co., Ltd. provides access to Bio X Cell’s complete product portfolio, including recombinant antibodies, ready‑to‑ship biosimilar and bispecific antibodies, and functional antibodies optimized for in vivo and advanced in vitro translational research. This partnership supports streamlined procurement workflows and research continuity for immunology, oncology, and translational biology programs in the region. 

Researchers in Chengdu and the surrounding Sichuan region may place orders for Bio X Cell pro ducts and services directly through Chengdu East Creative Technology Co., Ltd. For inquiries or to request a quote, please contact: 

Chengdu East Creative Technology Co., Ltd (Sichuan Province) 

No. 7 Consulate Road, South Tower of Poly Center, Room 202, Wuhou District, Chengdu, China 

Tel: 028-85222286 

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Expands Distribution in China Through Partnership with Chengdu East Creative Technology Co., Ltd. appeared first on BioXcell.

Founded in 2002, DAWINBIO Inc. is a leading life science distributor supporting the biopharmaceutical industry and academic research across South Korea. Headquartered in South Korea, DAWINBIO Inc. has established a nationwide distribution network and developed strong technical expertise across a broad range of life science applications. Through close collaboration with customers and partners, DAWINBIO Inc. has built long-term, trusted relationships grounded in scientific rigor, reliability, and service excellence.

In addition to supplying high-quality research reagents, DAWINBIO Inc. provides academic marketing and localized technical support, enabling researchers to stay informed of product developments and emerging technologies in their native language. This approach reflects DAWINBIO Inc.’s philosophy of continuous improvement and its commitment to delivering consistent, customer-focused support to the Korean life science community.

By partnering with DAWINBIO Inc., Bio X Cell expands its distribution footprint across South Korea’s rapidly advancing immunology, oncology, and translational research landscape. DAWINBIO Inc. will provide direct, local access to the full Bio X Cell portfolio, which features ultrapure, low-endotoxin functional antibodies specifically formulated for in vivo studies. Bio X Cell antibodies have also been validated in advanced in vitro applications, including organoid, organ-on-chip, and 3D spheroid model systems.

“Our priority is ensuring researchers have dependable access to antibodies that deliver consistent, reproducible performance in complex biological systems,” said Christopher Conway, CEO of Bio X Cell. “DAWINBIO Inc.’s scientific expertise, nationwide reach, and commitment to supporting researchers in South Korea makes them an ideal partner to strengthen local access to Bio X Cell’s in vivo-ready antibody portfolio.”

DAWINBIO Inc. provides access to the full Bio X Cell product portfolio, including recombinant antibodies, ready-to-ship biosimilar and bispecific antibodies, and functional antibodies optimized for in vivo and advanced in vitro translational research. As the authorized distributor of Bio X Cell products and services in South Korea, DAWINBIO Inc. will manage product ordering, shipping, delivery, and in-country technical support to ensure researchers receive authentic Bio X Cell reagents backed by full manufacturer assurances.

Researchers across the Republic of Korea can place orders for Bio X Cell products and services directly through DAWINBIO Inc. For inquiries or to request a quote, please contact:

DAWINBIO Inc.
601, ITECO, 150, Jojeong-daero, Hanam-city, Gyeonggi-do, South Korea
Tel: +82-1588-9741

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Appoints DAWINBIO Inc. as Distributor in South Korea appeared first on BioXcell.

Founded in 2008, Shandong Haosaitechnology Co., Ltd has established itself as a trusted scientific solutions provider, delivering a comprehensive portfolio spanning instruments, biological reagents, and experimental services. With integrated capabilities across technology R&D, technical design, and platform management, Shandong Haosaitechnology Co., Ltd supports researchers through the full lifecycle of their work, from early-stage technical guidance to post-sales support. Its regional footprint across Qingdao, Jinan, and Yantai enables responsive, localized service for a broad and growing scientific community.

This partnership reflects Bio X Cell’s continued investment in enabling reproducible, high-quality research at a regional level. Through Shandong Haosaitechnology Co., Ltd, researchers across Shandong Province will gain streamlined access to Bio X Cell’s portfolio of ultra-pure, low-endotoxin functional antibodies, engineered specifically for reliable performance in sensitive in vivo studies and advanced in vitro systems, including organoids and organ-on-chip models.

By combining Shandong Haosaitechnology Co., Ltd's technical infrastructure and regional expertise with Bio X Cell’s globally trusted antibody platform, the collaboration is designed to reduce procurement friction while increasing experimental confidence. Researchers will benefit from consistent access to antibodies manufactured to ≥95% purity, with endotoxin levels as low as ≤0.5 EU/mg, eliminating common sources of variability such as cytokine artifacts and off-target immune activation. Supported by nearly 30,000 peer-reviewed citations, Bio X Cell antibodies provide a reproducible foundation for immunology, oncology, and translational research workflows.

“Expanding our presence in China through strong regional partners is a critical part of our global strategy,” said Christopher Conway, CEO of Bio X Cell. “Shandong Haosaitechnology Co., Ltd brings a powerful combination of technical expertise, operational excellence, and customer-first values. Together, we are enabling researchers to access functional antibodies designed not just for binding, but for performance in complex biological systems.”

With this partnership, Bio X Cell continues to advance its mission of delivering functional antibodies that maintain consistency across murine, organoid, and human-relevant systems, supporting researchers as they move from discovery through translational validation with confidence.

Researchers in Shandong Province can now access Bio X Cell products directly through Shandong Haosaitechnology Co., Ltd. For inquiries or to request a quote, please contact:

Shandong Haosaitechnology Co., Ltd
Floor 4, Building 10, Jinan Biomedical Seience and Technology Park,
No. 30766, Jingshi East Road, Jinan, Shandong, China
Tel: 400-6947-688

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Strengthens Presence in Shandong Province Through Shandong Haosaitechnology Co., Ltd Partnership appeared first on BioXcell.

Founded in 2011 and headquartered in Suzhou, Realgen-bio Co., Ltd. has established itself as a trusted scientific partner to more than 4,000 organizations, including leading biopharmaceutical companies, cell therapy innovators, and government research institutions. With branch offices across China and a portfolio representing nearly 20 globally recognized biotechnology brands, Realgen-bio delivers integrated access to instruments, reagents, and consumables supporting both research and production-scale workflows.

Realgen-bio’s strength lies in its ability to connect high-performance technologies with real-world scientific applications. By providing systematic solutions across molecular biology, immunology, oncology, stem cell research, and neurobiology, the company enables researchers to move efficiently from discovery through translational and manufacturing stages.

Through this partnership, Bio X Cell strengthens its commitment to enabling reproducible, high-fidelity research in complex biological systems by expanding local access across China. Realgen-bio will provide researchers with streamlined access to Bio X Cell’s portfolio of functional antibodies, supporting a broad range of applications from in vivo studies to advanced in vitro systems, including organoid and organ-on-chip models.

Realgen-bio’s national infrastructure and technical expertise extend the reach of Bio X Cell’s globally validated antibody platform, trusted in nearly 30,000 peer-reviewed publications. These functional antibodies combine validated activity with ultrapure formulations (≥95% purity) and endotoxin levels as low as ≤0.5 EU/mg, providing the consistency and reliability required across diverse experimental workflows.

“China represents one of the most dynamic and fast-growing regions for life science and translational research,” said Christopher Conway, CEO of Bio X Cell. “Realgen-bio’s deep scientific engagement and strong customer relationships make them an ideal partner to expand access to antibodies designed for performance in living systems. This partnership ensures researchers can generate reproducible, biologically meaningful data across a wide range of applications and at every stage of their work.”

With this partnership, Bio X Cell continues to scale its global distribution network while reinforcing its role as the standard for functional antibodies, supporting researchers as they advance from mechanistic discovery to translational validation without compromising data integrity.

Researchers across China can now access Bio X Cell products directly through Realgen-bio Co., Ltd. For inquiries or to request a quote, please contact:

Jiangsu Real-gen Biotechnology Co., Ltd
Room A2-1003, No. 388 Xinping Street
Suzhou Industrial Park, China
Tel: +86 (512) 6558-5482
Email: sales@realgen-bio.com

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Expands Distribution in China Through Partnership with Realgen-bio Co., Ltd. appeared first on BioXcell.

Headquartered in Hangzhou, Bio-smile (Hangzhou) Biotechnology Co., Ltd. is a high-tech life sciences company integrating product sales, technical promotion, after-sales service, and technology development. Guided by its core values of honesty, sincerity, and integrity, Bio-smile is committed to delivering professional, high-quality, and responsive service to the scientific community. The company has established strong partnerships with universities, hospitals, research institutes, biopharmaceutical companies, and government laboratories across Eastern China.

As a trusted regional partner, Bio-smile provides researchers with reliable access to advanced life science tools, supported by technical expertise and a deep understanding of local research needs. Their established network and service-oriented approach position them to effectively support a broad range of scientific applications, from basic discovery through translational research.

Through this partnership, Bio X Cell expands its global distribution network and strengthens access to its portfolio of functional antibodies across key research regions in China. Bio-smile will provide local access, technical support, and streamlined procurement for Bio X Cell’s ultrapure, low-endotoxin (≤0.5 EU/mg), carrier-free antibodies trusted by scientists worldwide and cited in nearly 30,000 peer-reviewed publications.

Bio X Cell antibodies are specifically designed for performance in living systems, enabling reproducible results across in vivo studies and advanced in vitro models. With consistent lot-to-lot quality, scalable manufacturing, and formulations free from preservatives and stabilizers, Bio X Cell sets the global standard for functional antibodies, supporting reliable pathway interrogation and translational continuity from early discovery through complex biological systems.

“Expanding our partnership network with organizations like Bio-smile ensures that researchers have direct access to antibodies they can trust for reproducible, high-quality data,” said Christopher Conway, CEO of Bio X Cell. “Bio-smile’s strong regional presence and commitment to scientific service makes them an excellent partner to support the growing research community in Eastern China.”

Together, Bio X Cell and Bio-smile will enable researchers across Zhejiang and Fujian Provinces to access functional, in vivo-ready antibodies that reduce experimental variability, preserve biological integrity, and support consistent results across a wide range of research applications.

For inquiries or to request a quote, please contact:

Bio-smile
5nd floor, Building B, Jiangnan xingzuo
No.143 Jiangnan Avenue, Binjiang Zone
Hangzhou, China
Tel: 0571-87567650
Email: techservice@bio-smile.cn 

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Appoints Bio-smile as Distributor for Zhejiang and Fujian Provinces in China appeared first on BioXcell.

Headquartered in Chennai, GeneX India Bioscience Pvt. Ltd. is a leading life sciences solutions provider dedicated to advancing research and innovation across India. Since its founding in 2004, GeneX has built a strong reputation for delivering high-quality products and technical expertise across molecular biology, cell culture, genomics, proteomics, and biopharmaceutical research.

As a trusted partner to research institutes, diagnostic laboratories, and biotech R&D centers, GeneX combines globally recognized technologies with deep scientific support. Their experienced team enables cutting-edge research in gene and cell therapy, diagnostics, and translational science, aligning closely with Bio X Cell’s mission to support reproducible, high-quality research in complex biological systems.

Through this exclusive partnership, Bio X Cell expands its support for the rapidly growing immunology and oncology research communities across South and West India, with GeneX providing local access, technical guidance, and responsive support for its portfolio of ultrapure, low-endotoxin (≤0.5 EU/mg), carrier-free functional antibodies. Researchers benefit from direct access to authentic Bio X Cell reagents backed by a 1-year stability guarantee and supported by a 100% PhD-level scientific team, ensuring confidence in reagent integrity and every stage of study execution.

“Through our partnership with GeneX, researchers across South and West India will gain faster, more reliable access to functional antibodies designed for performance in living systems,” said Christopher Conway, CEO of Bio X Cell. “By combining Bio X Cell’s ultrapure, low-endotoxin antibody portfolio with GeneX’s strong scientific support and regional expertise, we are enabling scientists to generate reproducible results they can trust across complex biological systems.”

Together, Bio X Cell and GeneX will empower researchers across India to generate more reliable and biologically accurate data, accelerating discovery across immunology, oncology, and next-generation therapeutic development. For inquiries or to request a quote, please contact: 

GeneX 
#7, Paul Square,
Janakpuri 1st Street, Velachery,
Chennai, India – 600 042
Tel: +91 44 2243 2622 / 23
Email: customer.support@genexindia.net

About Bio X Cell 
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.

The post Bio X Cell Appoints GeneX as Exclusive Distributor for South and West India appeared first on BioXcell.

Through this partnership with Biogene India, Bio X Cell aims to further enable researchers across North and East India with easier access to its portfolio of functional, ultra-pure, low endotoxin antibodies formulated specifically for sensitive in vivo, ex vivo, and New Approach Methodologies (NAM) such as organoids, organs-on-chip, and spheroids research. Biogene India will handle all aspects of product procurement, support, and warranty for Bio X Cell products throughout North and East India. This partnership between Bio X Cell and Biogene India ensures Indian researchers receive authentic reagents fully covered by the Bio X Cell 1-year stability and self-life guarantee as well as full access to the 100% PhD level Bio X Cell technical support team for study support. 

The Biogene India order process is already well-established for the Indian research community and requesting products is fast and user-friendly. Researchers seeking Bio X Cell products in North and East India through Biogene India will receive dedicated guidance on product selection, facilitated centralized ordering, and help consolidating Bio X Cell offerings to efficiently source reagents. Supported by well-established institutional relationships, Biogene India will also expedite order processing for Bio X Cell products through priority handling. 

“We’re thrilled to appoint Biogene India as our distributor in for North and East India,” said Christopher Conway, CEO of Bio X Cell.“Their three decades of experience, strong institutional network, and commitment to customer service align perfectly with our mission to enable scientific discovery through seamless access to premium antibody products and services. By consolidating our authorized channel, we guarantee that researchers receive genuine products, dedicated support, and full warranty protection.”

Researchers across North and East India can now confidently access Bio X Cell products through Biogene India. For inquiries or to request a quote, please contact: 

Biogene India 
20A, 2nd Floor, Shivaji Marg, Najafgarh Road, New Delhi 110015, India 
Tel: +91 11 4258 1008 / +91 98111 61128 
Email: salescoordinator@biogene-india.com; customerservicerep@biogene-india.com 

About Bio X Cell  

Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Allowing experiments to seamlessly scale from milligrams to grams, researchers can confidently progress from discovery through translational studies without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world.    

The post Bio X Cell Appoints Biogene India as Distributor for North and East India appeared first on BioXcell.

As organoid and organ-on-chip systems become integrated into translational research, ensuring mechanistic continuity between traditional in vivo models and next-generation human-relevant platforms emerges as a key challenge. Variability in reagent purity, formulation, and validation standards complicates cross-model study interpretation and introduces unnecessary experimental noise.

Bio X Cell’s functional antibodies are engineered for performance in living systems, supporting reproducible blocking, depletion, activation, and neutralization studies. Their carrier-free, low-endotoxin formulations are designed to minimize reagent-driven effects in both murine in vivo models and sensitive 3D organoid systems.

Maintaining identical antibody formulations across the translational workflow allows researchers to use the same reagents as they move from animal studies to human-relevant models, reducing experimental variability and minimizing time spent on reagent revalidation. This supports more efficient and consistent progression across studies.

Peer-reviewed studies show that organoid systems are particularly sensitive to reagent quality, where impurities, endotoxin, and formulation differences can impact biological readouts. Using consistent antibody formulations across model systems helps reduce this source of variation and supports more reliable interpretation of results, particularly in cytokine- and immune-driven assays.

All Bio X Cell antibodies are manufactured to the company’s in vivo-ready quality standards for purity, concentration, and ultra-low endotoxin levels. These carrier-free formulations ensure consistent lot-to-lot performance and help to minimize reagent-driven variability.

As Bio X Cell launches into setting new standards for organoid-ready reagents, the company is a proud sponsor of the 2026 Reproducibility in Science Symposium hosted by Frederick National Laboratory for Cancer Research in partnership with Hood College, where the company will present a scientific poster on its scalable in vivo-ready recombinant antibody platform designed to support consistent, low-endotoxin antibody generation for translational research.

“Organoid systems demand a higher standard of reagent integrity and reproducibility,” said Christopher Conway, CEO of Bio X Cell. “Using the same antibody across in vivo and organoid models helps researchers reduce variability and supports more consistent interpretation of results across studies.”

Bio X Cell antibodies are designed to modulate biology across in vivo and human-relevant systems. With milligram-to-gram scale availability, Bio X Cell supports research from early discovery through translational studies.

About Bio X Cell
Bio X Cell is the global leader of in vivo-ready antibodies, delivering consistent, high-purity, low-endotoxin antibody solutions to scientists worldwide. Cited in nearly 30,000 peer-reviewed publications, Bio X Cell antibodies drive discovery in cancer, immunology, immuno-oncology, neuroscience, and infectious disease. Bio X Cell antibodies deliver reliable, reproducible results across in vivo and in vitro organoid and organ-on-chip studies allowing researchers to confidently scale their experiments from milligrams to grams and progress from discovery through translational workflows without switching suppliers or compromising quality. Catalog products are always in stock, and custom services offer an industry-leading 4-week turnaround time. Bio X Cell is headquartered in the US and has regional distribution and logistics hubs in Germany and China. Bio X Cell partners with over 30 distributors to enable the shipping of antibody workflow solutions globally. By supporting every stage of the research workflow, Bio X Cell enables innovation that positively impacts patients and families across the world. Learn more at www.bxcell.com. 

Antibody Solutions Built for Breakthrough Discovery.

For more information, please visit bioxcell.com or contact marketing@bxcell.com.

The post Bio X Cell Demonstrates Consistent Antibody Performance Across In Vivo and Organoid Models appeared first on BioXcell.